A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer

NCT07358585 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Colon Cancer Adenocarcinoma

Interventions

DRUG: HLX43 dose 1 + HLX07
DRUG: HLX43 dose 2 + HLX07
DRUG: HLX43 dose 3 + Serplulimab
DRUG: HLX43 dose 4 + Serplulimab

Sponsor

Shanghai Henlius Biotech